Voyager Therapeutics, Inc. announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. As CFO at Vor Bio, Jorgensen oversaw finance, communications, facilities, GMP, and IT and raised over $400 million in public and private financings.

Prior to this, he managed global public and private healthcare investing, including in early-stage biotech companies, for the Qatar Investment Authority, the sovereign wealth fund of the State of Qatar. Previously, Jorgensen led pharma and biotech investing efforts on the all-cap equity healthcare team at Calamos Investments LLC, a diversified global investment firm. Before joining Calamos, he covered mid- and large-cap biotech companies as an equity research analyst at Stifel, Nicolaus & Company, Incorporated.

Prior to entering the financial sector, Jorgensen investigated the pathobiology of Parkinson?s disease as a postdoctoral scientist at the Columbia University Irving Medical Center. He received his MBA from the Cornell SC Johnson College of Business, his Ph.D. in neuroscience from the University of Minnesota, and his B.A. from St. John?s University.